Company / Operating Income
Intellia Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$441.0M
FY2025
5-year range
-$534.3M / -$267.9M
FY2021-FY2025
Trend
+17.5%
vs FY2024
Sector context
#145 of 151
Health Care
What the data says
Among 151 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 4% for operating income. Operating Income returned to growth in FY2025 after 8 years of decline, reaching -$441M.
Based on SEC 10-K filings.
-$441M in FY2025.
Improved from -$515M to -$441M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 151This company -$441.0M Sector average $716.7M
▼
-161.5% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 17.5% year-over-year.
- Ranks #145 out of 151 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$441.0M | +17.5% |
| FY2024 | -$534.3M | -3.7% |
| FY2023 | -$515.3M | -12.5% |
| FY2022 | -$458.2M | -71.1% |
| FY2021 | -$267.9M | -96.1% |
| FY2020 | -$136.6M | -28.4% |
| FY2019 | -$106.4M | -17.1% |
| FY2018 | -$90.9M | -30.6% |
| FY2017 | -$69.6M | -116.3% |
| FY2016 | -$32.2M | -139.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026